SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Christensen E. Prognostic models in chronic liver disease: validity, usefulness and future role. J Hepatol 1997; 26: 14141424.
  • 2
    Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443450.
  • 3
    Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174182.
  • 4
    Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24: 861880.
  • 5
    Krowka MJ, Swanson KL, Frantz RF, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006 (in press).
  • 6
    Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492498.
  • 7
    Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494500.
    Direct Link:
  • 8
    Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65: 457459.
  • 9
    Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641648.
  • 10
    Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604606.
  • 11
    Rafanan AL, Maurer J, Mehta AC, Schilz R. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000; 118: 14971500.
  • 12
    Halank M, Wiemer M, Tschope C, Poller W, Schwimmbeck P, Horstkotte D, et al. [Precapillary pulmonary hypertension of uncertain etiology]. Dtsch Med Wochenschr 1998; 123: 861865.
  • 13
    Koneru B, Ahmed S, Weisse AB, Grant GP, McKim KA. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994; 58: 11331135.
  • 14
    Minder S, Fischler M, Muellhaupt B, Zalunardo MP, Jenni R, Clavien PA, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24: 703707.
  • 15
    Swanson K, Burger C, Rosen C, Steers J, Wiesner R, Krowka M. Survival in portopulmonary hypertension and orthotopic liver transplantation. Liver Transpl 2005; 11: C71.
  • 16
    Kawut SM, Krowka MJ, Roberts KE, Benza RL, Shrestha R, Taichman DB, et al. A multicenter case-control study of portopulmonary hypertension. Am J Respir Crit Care Med 2006; A170.